To explore clinically relevant Oct4/Sox2-induced reprogramming events in GBM, we began by conducting bulk RNA sequencing (RNA-seq) on patient-derived neurospheres with and without the transgenic co-expression of Oct4 and Sox2, reprogramming transcription factors shown by us and others to induce tumor-propagating GSC phenotypes in GBM cells [5,9]. This evidence concerns the gene SOX2 and neoplasm.